Recurrent lung cancer patients benefit from proton therapy: study

Auction Alert - Premier Medical Depot - Closing Dec 2nd - Bid on Over 365 Lots

Recurrent lung cancer patients benefit from proton therapy: study

John W. Mitchell, Senior Correspondent | March 21, 2017
ASTRO Rad Oncology Proton Therapy
A five-year retrospective study of patients with reoccurring lung cancer and other thoracic tumors concluded that, contrary to common protocol, intensity-modulated proton therapy (IMPT) increased life expectancy with few serious side effects.

Study details were presented Friday at the Multidisciplinary Thoracic Cancers Symposium held in San Francisco.

"We've been using this technique at our cancer center for a few years. We believed the therapy was serving patients pretty well," Dr. Jennifer Ho, lead author and a resident in radiation oncology at the University of Texas MD Andersen Cancer Center in Houston, told HCB News. "This retrospective evidence supports the treatment."

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

The research team conducted a look-back at the medical records of 27 patients who received re-irradiation for thoracic tumors using the IMPT technique through prospective clinical trials at a single institution between 2011 and 2016. All patients had previously received curative thoracic radiotherapy.

They found that the follow-up median re-irradiation occurred at about 30 months. This yielded an average survival rate of 18 months. At one year, the majority of patients were free from local and regional relapse, and about half of patients were free from relapse after a year.

The study found that the higher the dose, the lower the reoccurrence or progression of the cancer.

Side effects were low as well, according to Ho. Only two of the 27 patients experienced moderate to severe long-term lung toxicity. No severe long-term esophageal side effects nor life-threatening toxicity were noted.

"Our median survival rate of 18 months is the highest I've seen in any studies. I believe the best rates achieved prior were 10 to 14 months," said Ho. "Patient selection is certainly a big factor."

She explained that physicians have to be selective in choosing patients they believe can tolerate the extra treatments. She also said that patients need about 30 months to recover from their initial radiotherapy treatment to have the stamina to be successful with the follow-up IMPT therapy.

Conventionally, patients for whom lung cancer has returned are offered pain and palliative care options, rather than continued treatment.

Lung cancer causes more deaths in the U.S. than any other cancer because it is aggressive and recurrence is common. Many patients are not candidates for surgery, and curative radiation therapy often damages surrounding organs.

"We are really excited going forward, and look forward to refining the treatment to help more patients," said Ho.

You Must Be Logged In To Post A Comment